According to Zacks, “Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis and psoriasis. The company’s product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. “
IMUX has been the topic of several other research reports. ValuEngine upgraded Immunic from a hold rating to a buy rating in a report on Saturday, October 5th. Chardan Capital restated a buy rating on shares of Immunic in a report on Thursday, September 19th.
Shares of NASDAQ IMUX opened at $7.37 on Monday. The business’s 50-day moving average is $8.09. Immunic has a 1-year low of $6.00 and a 1-year high of $46.80. The stock has a market cap of $74.56 million, a P/E ratio of -0.21 and a beta of 3.39.
Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.15). On average, research analysts anticipate that Immunic will post -3.9 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC purchased a new stake in Immunic during the 2nd quarter worth about $33,000. Vanguard Group Inc. purchased a new stake in Immunic during the 2nd quarter worth about $132,000. BlackRock Inc. purchased a new stake in Immunic during the 2nd quarter worth about $145,000. Independent Advisor Alliance purchased a new stake in Immunic during the 2nd quarter worth about $804,000. Finally, Omega Fund Management LLC purchased a new stake in Immunic during the 2nd quarter worth about $15,731,000. Institutional investors own 14.83% of the company’s stock.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
Recommended Story: What is the operating income formula?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.